A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D

OBJECTIVE: This two-stage Phase II study assessed the activity of single agent alisertib in patients with recurrent/persistent uterine leiomyosarcoma (uLMS). METHODS: Eligibility criteria included histologically-confirmed, recurrent or persistent uLMS, age ≥18, 1-2 prior cytotoxic regimens, and RECI...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Gynecol Oncol
Egile Nagusiak: Hyman, David M, Sill, Michael W, Lankes, Heather A, Piekarz, Richard, Shahin, Mark S, Ridgway, Mildred R, Backes, Floor, Tenney, Meaghen E, Mathews, Cara A., Hoffman, James S, Aghajanian, Carol, Hensley, Martee L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5260802/
https://ncbi.nlm.nih.gov/pubmed/28094040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.10.036
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak